TransMedics Group (NASDAQ:TMDX) Now Covered by Robert W. Baird

Equities researchers at Robert W. Baird started coverage on shares of TransMedics Group (NASDAQ:TMDX) in a report released on Tuesday, Benzinga reports. The brokerage set an “outperform” rating and a $200.00 price target on the stock. Robert W. Baird’s target price points to a potential upside of 25.39% from the company’s current price.

Other equities analysts also recently issued research reports about the company. Stephens increased their price target on TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Canaccord Genuity Group upped their price target on shares of TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a report on Thursday, August 1st. TD Cowen lifted their price objective on TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, June 7th. Needham & Company LLC assumed coverage on TransMedics Group in a research note on Wednesday, August 21st. They set a “buy” rating and a $208.00 target price for the company. Finally, Oppenheimer raised their target price on TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $174.30.

TransMedics Group Stock Down 3.3 %

TransMedics Group stock opened at $159.50 on Tuesday. The company has a market capitalization of $5.25 billion, a P/E ratio of -469.12 and a beta of 1.99. TransMedics Group has a 1-year low of $36.42 and a 1-year high of $177.37. The firm’s fifty day simple moving average is $155.95 and its 200-day simple moving average is $130.14. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. The company had revenue of $114.30 million during the quarter, compared to analysts’ expectations of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The business’s quarterly revenue was up 117.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.03) earnings per share. Sell-side analysts forecast that TransMedics Group will post 1.23 earnings per share for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Edward M. Basile sold 6,750 shares of the stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $149.96, for a total value of $1,012,230.00. Following the completion of the transaction, the director now owns 732 shares of the company’s stock, valued at $109,770.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. The disclosure for this sale can be found here. Insiders sold a total of 61,247 shares of company stock valued at $9,650,880 in the last quarter. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently modified their holdings of TMDX. Fidelis Capital Partners LLC acquired a new stake in TransMedics Group in the 1st quarter valued at $35,000. International Assets Investment Management LLC bought a new stake in shares of TransMedics Group in the 2nd quarter worth about $47,000. J.Safra Asset Management Corp grew its holdings in shares of TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after purchasing an additional 383 shares during the last quarter. Signaturefd LLC increased its position in shares of TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares in the last quarter. Finally, Amalgamated Bank lifted its holdings in TransMedics Group by 6.7% during the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after purchasing an additional 70 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.